CK Life Sciences affiliates Sealbond Limited and Conjoint Inc. filed Amendment No. 4 to Schedule 13D with the SEC on October 27, 2026, disclosing the October 26, 2026 closing of a private placement in which Sealbond purchased 4,098,360 shares of Dogwood Therapeutics, Inc. common stock at $1.22 per share for aggregate consideration of approximately $5,000,000.

Key Highlights

  • Private placement closed: Sealbond Limited purchased 4,098,360 shares of Dogwood Therapeutics common stock on October 26, 2026, at a purchase price of $1.22 per share.
  • Total consideration: Aggregate consideration for the purchase was approximately $5,000,000, funded from Sealbond's working capital.
  • Sealbond stake: Following the transaction, Sealbond directly holds 25,920,693 shares, representing approximately 67.8% of the outstanding common stock.
  • CK Life Sciences combined stake: CK Life Sciences Int'l., (Holdings) Inc., as indirect parent of both Sealbond and Conjoint Inc., may be deemed to beneficially own 28,763,331 shares, or approximately 75.2% of the outstanding common stock.
  • Conjoint Inc. position: Conjoint Inc. directly holds 2,842,638 shares, representing approximately 7.4% of the outstanding common stock.
  • Share count basis: All ownership percentages are calculated on a base of 38,227,913 shares outstanding, comprising 34,129,553 shares as of September 30, 2026, plus the 4,098,360 shares issued in the private placement.

CK Life Sciences Affiliates Increase Dogwood Therapeutics Ownership via October 2026 Private Placement

According to the filing, Sealbond Limited, a British Virgin Islands company, closed the private placement on October 26, 2026, purchasing 4,098,360 shares of Dogwood Therapeutics, Inc. common stock ($0.0001 par value) directly from the company at $1.22 per share. The aggregate consideration was approximately $5,000,000, paid from working capital. The transaction had been described in a prior Subscription Agreement referenced in Amendment No. 3, filed October 21, 2026.

The filing discloses that Sealbond now directly holds 25,920,693 shares, equal to approximately 67.8% of the outstanding common stock. Conjoint Inc., a Delaware company and a separate direct holder, owns 2,842,638 shares, or approximately 7.4%. CK Life Sciences Int'l., (Holdings) Inc., a Cayman Islands company and the indirect parent of both Sealbond and Conjoint, is reported as beneficially owning 28,763,331 shares in aggregate, representing approximately 75.2% of the outstanding common stock, by virtue of its voting and dispositive power over shares held by its subsidiaries.

This Amendment No. 4 updates the original Schedule 13D filed on October 15, 2024, and its three prior amendments. The filing states that except as specifically amended, the prior Schedule 13D disclosure remains in full force and effect. The issuer, Dogwood Therapeutics, Inc., is headquartered at 44 Milton Avenue, Alpharetta, Georgia 30009, according to the filing.

What Was Disclosed

Sealbond Limited, an affiliate of CK Life Sciences, completed the purchase of 4,098,360 Dogwood Therapeutics shares at $1.22 per share for approximately $5,000,000 on October 26, 2026, raising the CK Life Sciences group's combined beneficial ownership to approximately 75.2% of the company's common stock.